Association Between Plasma Melatonin and No-reflow

Completed

• Conditions: ST-segment Elevation Myocardial Infarction

• Registration Number: NCT03306303
• Lead Sponsor: Chinese PLA General Hospital

Brief Summary

ST-segment elevation myocardial infarction (STEMI) is an acute manifestation of coronary heart disease, remaining a frequent cause of death. A better understanding of risk factors and pathogenic mechanisms underlying STEMI may help improve the prognosis and life quality of these patients. Melatonin is the chief indoleamine produced by the pineal gland, and a well-known antioxidant and free radical scavenger. Basic studies have showed that melatonin is associated with myocardial infarction and heart failure. However, no study has evaluated whether melatonin is associated with adverse clinical outcomes in STEMI patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-01-01
• Status Verified: 2017-10
• Primary Completion: 2017-10-01
• Study Completion: 2017-10-01
• Study First Submitted: 2017-10-02
• Study First Submitted QC: 2017-10-04
• Last Update Submitted: 2017-10-04
• Study First Posted: 2017-10-11
• Last Update Posted: 2017-10-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1700

Inclusion Criteria

a diagnosis of STEMI and needed PCI

Exclusion Criteria

patients with cancer patients who used melatonin

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
a change in the prevalence of no-reflow	mediately after percutaneous coronary intervention (PCI)	Thrombolysis in myocardial infarction (TIMI) flow grade of \<3 with a myocardial blush grade of 0-1 was defined as angiographic no-reflow

Secondary Outcome Measures

Name	Time	Method
in-hospital major adverse cardiac or cerebrovascular events	up to 2 weeks after PCI	the composite of death, nonfatal MI, or stroke
in-hospital complications	up to 2 weeks after PCI	defined as acute heart failure, atrial fibrillation, chest pain or recurrence of myocardial infarction, complete atrioventricular block, cerebrovascular disease, ventricular fibrillation or ventricular tachycardia